Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma

Nyakale, Nozipho; Filippi, Luca; Aldous, Colleen; Sathekge, Mike

doi:10.3390/cancers15071975

Cited by 5 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yang et al explored the biological behavior of HCC with PVTT and used tumor biomarkers such as alphafetoprotein (AFP) and SUV max to identify patients who may be suitable for liver transplants [6]. They found elevated AFP levels often corresponded with more aggressive HCC cases [6,39]. Advanced tumor stages, PVTT, and large and multiple tumors were also associated with positive 18F-FDG PET/CT results [40].…”

Section: The Role Of 18f-fdg Pet/computed Tomography In the Diagnosis...mentioning

confidence: 99%

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Mititelu,

Mitoi,

Mazilu

et al. 2024

Nuclear Medicine Communications

View full text Add to dashboard Cite

Portal vein thrombosis, a relatively frequent complication associated with hepatocellular carcinoma (HCC) and liver cirrhosis, is recognized as a significant global health concern. This is mainly due to these conditions’ high prevalence and potentially severe outcomes. The aim of our study was to conduct a comprehensive literature review to evaluate the efficacy, accuracy, and clinical implications of 18F-FDG PET-CT in diagnosing and managing portal vein tumor thrombosis (PVTT) in patients with HCC. HCC, which accounts for 80% of liver malignancies, ranks as the fourth most prevalent cancer globally and is a significant contributor to cancer-related mortality. The majority of HCC patients are diagnosed at an advanced stage, leading to a deterioration in patient outcomes. Involvement of the portal vein is also a significant negative factor. This review analyzes the application of 18F-FDG PET-CT in the detection and management of PVTT in patients with HCC, with an emphasis on the importance of the maximum standardized uptake value as an essential diagnostic and prognostic marker. 18F-FDG PET-CT is invaluable for detecting recurrence and guiding management strategies, particularly in patients with high-grade HCC, and plays a pivotal role in differentiating malignant portal vein thrombi from their benign counterparts.

show abstract

Section: The Role Of 18f-fdg Pet/computed Tomography In the Diagnosis...mentioning

confidence: 99%

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Mititelu,

Mitoi,

Mazilu

et al. 2024

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…A few radiotracers that perform better than 18 F-FDG have been documented in hepatocellular carcinoma. Of these, acetate, a precursor of phosphatidylcholine, exhibits high sensitivity, especially for well-differentiated tumors [12]. 11 C-acetate and 18 F-FDG have complementary roles in the detection of hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Modulation of FDG Uptake by Cell Cycle Synchronization Using a T-Type Calcium Channel Inhibitor

Yoon,

Kang

2023

Cancers

View full text Add to dashboard Cite

Background: We investigated whether cell cycle synchronization induced by the T-type calcium channel inhibitor mibefradil could increase tumoral 2-[18F] fluoro-2-deoxy-d-glucose (FDG) uptake in vitro and in vivo. Methods: Human prostate cancer cells (PC-3) were treated with 10 μM mibefradil for 24, 48, and 72 h to induce G1 arrest. Cell cycle distribution was analyzed at 0, 4, 8, 12, 15, 18, and 24 h after mibefradil withdrawal. Cellular uptake was measured after incubating cells with [3H] Deoxy-d-Glucose (DDG) for 1 h at the same time points used in the cell cycle analysis. The correlation between [3H] DDG uptake and each cell cycle phase was evaluated in the early (0–12 h) and late phases (15–24 h) of synchronization. In vivo FDG PET imaging was performed in PC-3-bearing mice at baseline, 24 h, and 48 h after mibefradil treatment. Results: The G0/G1 fraction of PC-3 cells was significantly increased from 33.1% ± 0.2% to 60.9% ± 0.8% after 24 h mibefradil treatment, whereas the S and G2/M fractions were decreased from 36.3% ± 1.4% to 23.2% ± 1.1% and from 29.7% ± 1.3% to 14.9% ± 0.9%, respectively, which were similar to the results by serum starvation. Mibefradil treatment for 24, 48, and 72 h increased the number of cells in S phase at 18–24 h after withdrawal; however, only the 72 h treatment increased [3H] DDG uptake (145.8 ± 5.8% of control at 24 h after withdrawal). [3H] DDG uptake was positively correlated with the size of the S phase fraction and negatively correlated with the size of the G0/G1 fraction in the late phase of synchronization. DDG uptake was significantly increased by mibefradil-induced cell cycle synchronization and correlated with the sizes of cell cycle fractions. In vivo FDG PET imaging also demonstrated a significant increase in tumor uptake after mibefradil treatment. Quantified tumor FDG uptake (%ID/g) increased from 4.13 ± 2.10 to 4.7 ± 2.16 at 24 h, and 5.95 ± 2.57 at 48 h (p < 0.05). Conclusion: Cell cycle synchronization could be used to increase the diagnostic sensitivity of clinical FDG positron emission tomography.

show abstract

Hyperpolarized ¹³C Pyruvate MRI: An Important Window into Tumor Metabolism

Ohliger

2024

Radiology: Imaging Cancer

View full text Add to dashboard Cite

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma

Cited by 5 publications

References 80 publications

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Modulation of FDG Uptake by Cell Cycle Synchronization Using a T-Type Calcium Channel Inhibitor

Hyperpolarized ¹³C Pyruvate MRI: An Important Window into Tumor Metabolism

Contact Info

Product

Resources

About

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma

Cited by 5 publications

References 80 publications

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Advancements in hepatocellular carcinoma management: the role of 18F-FDG PET-CT in diagnosing portal vein tumor thrombosis

Modulation of FDG Uptake by Cell Cycle Synchronization Using a T-Type Calcium Channel Inhibitor

Hyperpolarized 13C Pyruvate MRI: An Important Window into Tumor Metabolism

Contact Info

Product

Resources

About

Hyperpolarized ¹³C Pyruvate MRI: An Important Window into Tumor Metabolism